Liquid Biopsy Market to Grow at 18% CAGR by 2033, Propelled by Liquid Biopsy Adoption in Oncology

The global liquid biopsy market size is estimated at US$ 4.72 billion in 2023 and is forecasted to expand rapidly at a CAGR of 18% to reach a valuation of US$ 24.70 billion by 2033, according to a newly released market study of liquid biopsy by Fact.MR, a market research and competitive intelligence provider. This growth is driven by the increasing demand for non-invasive cancer diagnostics, advancements in next-generation sequencing (NGS) technologies, and the rising prevalence of cancers worldwide. Liquid biopsies, which analyze circulating tumor DNA (ctDNA), RNA, and other biomarkers in blood or fluids, offer real-time insights into tumor dynamics, enabling early detection, therapy selection, and monitoring without the risks of traditional tissue biopsies.


For More Insights into the Market, Request a Sample of this Report: https://www.factmr.com/connectus/sample?flag=S&rep_id=9040

The market's expansion reflects the shift toward precision medicine, supported by regulatory approvals and collaborations between biotech firms and healthcare providers, positioning liquid biopsy as a transformative tool in oncology.

Market Segmentation and Trends:

The liquid biopsy market is segmented by offering, sample, biomarker, technology, application, and region, providing a comprehensive view of its dynamics. Offerings include assay kits, instruments, and software & services, with assay kits leading due to their role in standardized testing. Samples encompass blood, urine, saliva, and others, with blood dominating for its accessibility to ctDNA. Biomarkers include circulating tumor cells (CTCs), ctDNA, extracellular vesicles, and circulating tumor RNA, with ctDNA gaining traction for mutation detection. Technologies comprise NGS, PCR, and others, with NGS projected to grow at 19% CAGR for its high sensitivity.

Applications span routine screening, patient work-up, therapy selection, and treatment & recurrence monitoring, with therapy selection expanding rapidly for personalized medicine. Regionally, North America holds the largest share, while Asia Pacific is the fastest-growing at over 20% CAGR. Trends include the integration of AI for data analysis, multi-omics approaches, and the development of ultra-sensitive assays for early-stage cancer detection.

Driving Factors Behind Market Growth:

The liquid biopsy market is propelled by several key factors. The global cancer burden, with 20 million new cases in 2022 and projected 35 million by 2050, drives demand for non-invasive diagnostics. Liquid biopsies enable early detection and monitoring, reducing mortality through timely interventions. Advancements in NGS and PCR technologies offer high sensitivity for low-abundance biomarkers, facilitating precision oncology. The shift toward minimally invasive procedures minimizes patient discomfort and risks, boosting adoption in screening programs. Regulatory approvals, like FDA's for Guardant's Shield test in 2024, validate clinical utility.

Rising investments in biotech R&D, coupled with collaborations for companion diagnostics, accelerate innovation. The aging population and lifestyle factors increasing cancer incidence further fuel growth. Additionally, the cost-effectiveness of liquid biopsies compared to tissue biopsies supports their integration into healthcare systems, addressing accessibility in underserved regions.

Browse Full Report: https://www.factmr.com/report/liquid-biopsy-market

Recent Developments and Key Players:

The liquid biopsy market is witnessing rapid advancements, with key players focusing on sensitivity improvements and multi-cancer detection. In May 2025, Guardant Health and Pfizer collaborated to advance the Guardant Infinity platform for therapy development using smart liquid biopsy technology. At ASCO 2025, research highlighted liquid biopsy's role in switching to camizestrant for breast cancer recurrence, improving outcomes.

In April 2025, ASCO publications discussed ctDNA approaches for cancer characterization and residual disease detection. A 2025 PubMed review, "Cancer in a drop," summarized LB advances in solid tumors, noting doubled publications since 2020. In August 2025, studies improved ctDNA sensitivity for melanoma liquid biopsy.

Prominent players include Guardant Health, Natera, Exact Sciences Corporation, Illumina, Inc., F. Hoffmann-La Roche Ltd., Thermo Fisher Scientific Inc., Bio-Rad Laboratories, Inc., and QIAGEN N.V. Competitor analysis reveals a focus on NGS-based platforms and AI integrations. Guardant leads with multi-cancer tests like Shield, while Natera excels in ctDNA monitoring. Roche and Illumina dominate technology, with strategic acquisitions enhancing portfolios. Companies are investing in clinical trials and regulatory approvals to expand applications, targeting precision medicine in oncology.

Regional Insights and Opportunities:

North America dominates the liquid biopsy market, holding over 40% share in 2023, driven by advanced healthcare infrastructure and high cancer prevalence in the United States, supported by FDA approvals and R&D investments. Europe follows, with Germany and the UK benefiting from strong biotech sectors and screening programs. The Asia Pacific region is the fastest-growing at over 20% CAGR, led by China and India, where rising cancer cases and government initiatives for precision medicine fuel demand.

Latin America, particularly Brazil, offers opportunities through expanding oncology care. The Middle East & Africa show potential with improving diagnostics infrastructure. Emerging markets present growth via affordable testing and partnerships for technology transfer, addressing the rising cancer burden in low-resource settings.

Challenges and Future Outlook:

The liquid biopsy market faces challenges, including standardization issues, high costs for NGS-based tests, and limited reimbursement in developing regions. Sensitivity for early-stage detection and regulatory hurdles for new biomarkers also pose obstacles. However, the market's future is promising, with opportunities in AI-driven analysis and multi-omics integrations for comprehensive profiling.

As cancer incidences rise, advancements in ultra-sensitive assays and companion diagnostics will drive innovation. The market is well-positioned for sustained growth, nearly quintupling by 2033 through non-invasive, precise solutions that enhance oncology care.

Comments

Post a Comment

Popular posts from this blog

Polystyrene Market to Soar to USD 56.5 Billion by 2033 with 5.8% CAGR Growth

  Polystyrene market is projected to surge from USD 32.3 billion in 2023 to USD 56.5 billion by 2033, driven by a robust CAGR of 5.8%. Fueled by rapid urbanization, technological advancements, and growing demand in packaging, electronics, and construction, polystyrene remains a cornerstone material across multiple industries. This press release explores key growth drivers, projections, and opportunities for stakeholders in this versatile market. Why Is the Market Growing? The Polystyrene market is expanding due to its widespread use in packaging, electronics, and construction, driven by global urbanization and rising consumer demand. Expandable polystyrene (EPS) is a key driver, valued for its lightweight, durable, and insulating properties, particularly in flexible and rigid packaging, which holds significant market share. The electronics sector benefits from polystyrene’s affordability and versatility in producing components for consumer devices, fueled by increasing digitiz...
Read more

Cardiac Rehabilitation Devices Market to Expand by US$ 1.7 Billion by 2035, Driven by AI Solutions

The global Cardiac Rehabilitation Devices Market , valued at US$ 2.2 billion in 2025, is projected to reach US$ 3.9 billion by 2035, expanding at a CAGR of 5.8%. Driven by rising cardiovascular diseases, aging populations, and advancements in wearable technology, this market is vital for heart health recovery. This press release explores the key drivers, projections, and opportunities shaping this critical healthcare industry. Why Is the Market Growing? The increasing prevalence of cardiovascular diseases, with WHO reporting 17.9 million annual deaths globally, drives demand for rehabilitation devices. Aging populations, with 10% of the global population over 65 in 2024, boost the need for devices like treadmills and heart rate monitors. Innovations, such as Philips’ 2024 wearable ECG monitor, improve patient monitoring by 25%. Government initiatives, like the U.S.’s Medicare expansion for rehab programs, enhance access, while high costs, averaging US$ 5,000 per device, are mitigat...
Read more

Basecoater Market Advances with Smart and Efficient Coating Systems

  The global basecoater market , valued at US$ 352.3 million in 2024, is projected to grow at a compound annual growth rate (CAGR) of 4.2%, reaching US$ 532.1 million by 2034, according to a recent report by FactMR. This growth reflects the increasing demand for precision coating solutions in industries such as automotive, packaging, and electronics, driven by technological advancements and the need for durable, high-quality finishes. Market Dynamics and Key Drivers Basecoaters, specialized machines used to apply uniform base coatings to substrates, are critical in industries requiring precision and durability. These machines ensure consistent application of coatings, enhancing product aesthetics and functionality. The report highlights that the rising demand for eco-friendly and high-performance coatings, particularly in automotive and packaging, is a primary driver. The shift toward sustainable materials and processes is pushing manufacturers to adopt advanced basecoating tec...
Read more